Nursing Review Issue 04 Jul - Aug 2020 | Página 25

clinical practice we’ve got a lot to learn about it in terms of when is the best time to give it. What a lot of us have been looking at is repurposing medications used and developed for other indications and other conditions. The one that has had the most attention is an antimalarial drug called chloroquine, or a modification of it called hydroxychloroquine. Donald Trump, Clive Palmer and a variety of others have really advocated for its use and because of that there’s been a lot of political opinion, and there’s been a lot of poor science as well. There’s been what we call observational studies in which we’ve looked at the outcome of people without any selection as to who got what therapy. If you were looking at patients, a doctor may not give any therapy at all to someone who looks really well. They might give therapy to someone who looks really sick, and it wouldn’t be surprising, therefore, if the person who was already really sick would be the one who would have the higher death rate and you could easily assume, “Oh, that was because they got that particular medication,” whereas in fact, it might be their underlying illnesses. We always search for randomised trials, where we don’t have any bias at the beginning. We determine by the toss of the coin which patient gets which therapy. That’s the most rigorous way to work out if a drug like hydroxychloroquine actually works. The other thing is that these trials have to be big. They have to have typically well over a thousand patients. Otherwise, you may risk not really being able to show the benefits or otherwise of a particular therapy. I know that you are running trials in a few Queensland hospitals. Do you have enough sick patients in Queensland? The trial that we’re undergoing is called ASCOT – Australasian COVID-19 Trial. The trial randomises people into four different arms or four different choices. One is a person who doesn’t get any antiviral drug. The second is they get the malaria drug, hydroxychloroquine. The third is that they get the HIV drug called lopinavir and ritonavir. The fourth possibility is they get the hydroxychloroquine and the HIV drug. We’ve had 70 hospitals in Australia and another 11 in New Zealand agree to take part in this study. Now there is a thing called Lasagna’s Law. Lasagna was a very famous clinical trials expert in the 60s and 70s and he came up with this law that as soon as you design the most perfect randomised trial, suddenly the patients with the condition that you want to treat and to put into this trial disappear, and of course, they come back again when the trial is over. Unfortunately, in Australia and New Zealand, because we’ve had such great efforts in social distancing and control of the spread of the infection, we’ve got no patients to enrol in the study. So we are having to look internationally, whether that’s in Southeast Asia, or whether we collaborate with colleagues in the US and Europe and potentially Latin America. Had you enrolled any patients in the trial before the curve was flattened? It’s a good news, bad news story. The good news is that when the hospitals opened for enrolment, suddenly they had no patients who were eligible. We really are committed to doing the trial though. One feature about the trial is that it’s got what’s called an adaptive design, which means instead of being rigid and fixed in terms of what we are going to study, if we see data that comes from an overseas trial, we are quite prepared to change the options. It might be that the HIV drug or the malaria drug don’t end up being used, but something new from the US or from Europe is slotted into the trial depending on data that’s come through when we’re ready to start the study. This is the key study being done in Australia and New Zealand. At the same time, there is a huge amount of work being done on vaccine development. You’ve got to really, first of all, develop a vaccine that has a chance of working. In other words, ensuring it is something that stimulates the immune system to prevent an infection. Then you’ve got to work out, is it safe? Historically there have been vaccines that have not had a great safety profile. Thirdly, you’ve got to work out if this vaccine produces lifelong immunity, and what is the schedule you need to give? There are some vaccines where you have the vaccine and then you might have a booster six months later. There’s a lot of work to be discovered as to what is the right regimen. Then how do you ramp up production so that billions of people around the world can get the vaccine? So there is an awful lot, that normally takes 10 to 15 years, realistically, that has to be compressed into a very short period of time. That’s our challenge. I don’t think we can truly imagine that there’ll be a vaccine out in 2020. By the time you ramp up production, who decides who gets it, is it only to be given to the elderly in nursing homes? Is it only to be given to healthcare workers? When do we have the capacity to really say that we have a safe world where we’ve got protection against this novel coronavirus? In your experience, how often do we find solutions for a sickness using existing drugs? One of the most famous or infamous examples was Thalidomide, a drug used in the 1960s to prevent morning sickness in women. Notoriously, it was found to have very, very serious birth defects in the children of the mothers who took it. But then interestingly, that drug was also found to be effective in treating myeloma, a type of blood cancer, obviously with very strict conditions. That is one example of where the drug was successfully used in a completely different disease process. One interesting opportunity is that antimalarials and anti-HIV drugs are both given by mouth, and both do have a history of being used for long periods of time in certain people. And so, that raises the potential that you could even give one of these medications as a preventative, but that would again require large trials. We’ve got to be sure that the safety of those medications is sufficient that if you were giving it to large numbers of people who were actually healthy, trying to prevent infection, that you could give it safely with benefits, but without significant risks. We don’t have answers yet. We’ve got trials underway, but let’s wait eagerly to see the results so that we really do know how we’re going to move forward. You’re working on something where the whole world is absolutely hanging out and waiting for you guys to solve it. How is that kind of pressure? Is it strange? It’s strange, but it’s something that has happened before. When I was a medical student and then when I was a junior doctor, every one of my patients with HIV died. We had a situation there where, with a lot of stimulus funding, we were able to move ahead. I’ve just come from my HIV clinic and my patients are taking one pill once a day and leading completely normal lives. That’s what the infectious diseases profession has been able to do in the past. We’re eager to solve this problem of the novel coronavirus so we can do it again. ■ nursingreview.com.au | 23